Elixir Medical Corporation products
DESyne - Novolimus Eluting Coronary Stent System
The DESyne X2 Novolimus Eluting Coronary Stent System is a low-profile DES with high flexibility and exceptional deliverability. The ultra-thin design of its stent and polymer coating, with no primer coating, results in one of the thinnest coated struts available.
DESyne - Novolimus-Eluting Coronary Stent System
The DESyne BD Novolimus-Eluting Coronary Stent System represented a significant advancement in biodegradable coating technology, eliminating the need for a primer coating and achieving a bare metal surface within six to nine months, while providing excellent DES results.
Novolimus - Metabolite Drug
Novolimus is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.
Sirolimus - mTOR inhibitor
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, DESyne® BD and the fully resorbable DESolve® and DESolve® Cx scaffolds have resulted in excellent clinical outcomes and sustained safety and effectiveness.
DynamX - Drug Eluting Coronary Bioadaptor System
The DynamX Drug Eluting Coronary Bioadaptor System is a significant innovation in the treatment of coronary artery disease. Going beyond drug-eluting stents (DES), DynamX represents one of the most significant breakthroughs in implant design in the past 30 years.